[1] Thursz M, Gual A, Lackner C, et al. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol, 2018, 69: 154-181.
[2] Thursz MR, Richardson P, Allison M, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med, 2015, 372: 1619-1628.
[3] Hsu BB, Gibson TE, Yeliseyev V, et al. Dynamic Modulation of the Gut Microbiota and Metabolome by Bacteriophages in a Mouse Model. Cell Host & Microbe, 2019, 25:803-814.e5.
[4] Duan Y, Llorente C, Lang S, et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature, 2019, 575: 505-511.
[5] Llopis M, Cassard AM, Wrzosek L, et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut, 2016, 65: 830-839.
[6] Xiao J, Zhang R, Wu Y, et al. Rice Bran Phenolic Extract Protects against Alcoholic Liver Injury in Mice by Alleviating Intestinal Microbiota Dysbiosis, Barrier Dysfunction, and Liver Inflammation Mediated by the Endotoxin-TLR4-NF-κB Pathway. J. Agric. Food Chem, 2020, 68: 1237-1247.
[7] Górski A, Weber-Dabrowska B. The potential role of endogenous bacteriophages in controlling invading pathogens. CMLS, Cell. Mol. Life Sci, 2005, 62: 511-519.
[8] Schooley RT, Biswas B, Gill JJ, et al. Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection. Antimicrob Agents Chemother, 2017, 61:e00954-17.
[9] Dedrick RM, Guerrero-Bustamante CA, Garlena RA, et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med, 2019, 25: 730-733.
[10] Ott SJ, Waetzig GH, Rehman A, et al. Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients With Clostridium difficile Infection. Gastroenterology, 2017, 152:799-811.e7.
[11] Zuo T, Wong SH, Lam K, et al. Bacteriophage transfer during faecal microbiota transplantation in Clostridium difficile infection is associated with treatment outcome. Gut, 2018, 67: 634-643.
[12] Cox CR, Coburn PS, Gilmore MS. Enterococcal cytolysin: a novel two component peptide system that serves as a bacterial defense against eukaryotic and prokaryotic cells. CPPS, 2005, 6: 77-84.
[13] Van Tyne D, Martin MJ, Gilmore MS. Structure, function, and biology of the Enterococcus faecalis cytolysin. Toxins, 2013, 5: 895-911.
[14] ?usiak-Szelachowska M, Weber-D?browska B, Jończyk-Matysiak E, et al. Bacteriophages in the gastrointestinal tract and their implications. Gut Pathog, 2017, 9: 44. |
